Sividon Diagnostics, a Köln, Germany-based developer of innovative products to help improving therapy selection in cancer, has received an equity investment of undisclosed amount.
Investors include Creathor Venture, Rheinland Venture Capital and KfW.
The company intends to use the funds to develop and market innovative invitro diagnostics.
Led by managing directors Dr. Christoph Petry and Dr. Georg Kox, Sividon is launching the EndoPredict® assay for pathology laboratories, which allows a significantly improved risk assessment of breast cancer. The company is also focusing on developing further products in breast cancer and other oncological indications out of its well-filled pipeline.
Sividon is a spin-off from the diagnostics division of Siemens Healthcare.